Skip to content
MarketNewsAPI
Product Live news Screener Coverage Pricing
Docs Overview REST API WebSocket API MCP server
Resources Use cases Blog Changelog Status Compare Contact
Log in Get API key Dashboard
GPTRF$0.19-0.01(-5.14%)Grande Portage Resources Ltd. to Attend the 52nd Annual New Orleans Investment Conference[12:14:00 PM ET]ORCL$131.58+5.52(+4.38%)Oracle Reinvents Enterprise Computing for the AI Era with OpenAI Oracle AI World -- Oracle today announced a major new collaboration with OpenAI to redefine how the world's businesses run in the age of AI. By...[12:08:00 PM ET]ORCL$131.58+5.52(+4.38%)Oracle Brings Google TPUs to Oracle Cloud Infrastructure Oracle AI World -- Oracle and Google today announced that Google's Tensor Processing Units (TPUs) will be available through Oracle Cloud...[12:07:00 PM ET]SMP$37.43+0.15(+0.40%)Standard Motor Products, Inc. Announces Third Quarter 2026 Earnings Conference Call Standard Motor Products, Inc. (NYSE: SMP), a leading automotive parts manufacturer and distributor, is scheduled to report its earnings for the three ...[12:06:00 PM ET]SNOW$340.24+5.29(+1.58%)Oracle Expands Native AI and Data Services on OCI with Snowflake Oracle AI World -- Oracle and Snowflake (NYSE: SNOW) today announced that Snowflake AI Data Cloud will be available as a native, first-party service...[12:06:00 PM ET]ORCL$131.58+5.52(+4.38%)Oracle Advances Enterprise Security for the AI Era Oracle AI World -- Oracle today announced Oracle AI Security Mesh, powered by OpenAI. The new offering complements Oracle Cloud Infrastructure (OCI)...[12:05:00 PM ET]ORCL$131.58+5.52(+4.38%)Oracle Introduces Oracle Media Fabric Oracle AI World -- Oracle today announced Oracle Media Fabric, an integrated platform designed to help media companies, streaming providers, and...[12:04:00 PM ET]ORCL$131.58+5.52(+4.38%)Oracle Unveils New Cloud Networking Innovations for AI Oracle AI World -- Oracle today announced new capabilities in Oracle Acceleron, Oracle Cloud Infrastructure's (OCI) suite of networking and...[12:03:00 PM ET]ADT$6.89+0.00(+0.07%)ADT Secures AI Innovation with Oracle Oracle AI World -- ADT Inc. (NYSE: ADT), the trusted leader in smart home security solutions, is expanding its use of AI with Oracle AI...[12:02:00 PM ET]ORCL$131.58+5.52(+4.38%)Oracle Expands Fusion Data Intelligence with New Deep Insight Agents, Operational Analytics, and AI Capabilities Oracle AI World -- Oracle today announced new Oracle Fusion Data Intelligence capabilities that help customers uncover insights closer to the...[12:01:00 PM ET]WDFN$38.500.00(0.00%)Woodlands Financial Services Company Announces Fourth Quarter Cash Dividend[12:00:00 PM ET]CBRS$118.00+9.63(+8.89%)Cerebras and Oracle Team Up to Bring Cerebras AI Inference to Oracle Cloud Infrastructure[12:00:00 PM ET]IVZ$28.96+0.42(+1.49%)Invesco Announces Work with Anthropic to Bring its Custom Portfolio and Practice Management Capabilities to Claude Invesco Ltd. (NYSE: IVZ), a leading global asset management firm, announced today it is working with Anthropic to bring its data to support portfolio ...[12:00:00 PM ET]MSGM$4.47-0.17(-3.56%)Motorsport Games' Proprietary RaceControl Platform Powers Record Concurrent Players for Le Mans Ultimate in Biggest 24 Hours of Le Mans Online Event Yet[12:00:00 PM ET]ORCL$131.58+5.52(+4.38%)Oracle AI Data Platform Brings AI-Assisted Business Context to Enterprise AI Oracle AI World -- Oracle today announced new Oracle AI Data Platform capabilities that help customers build, deploy, and scale enterprise AI by...[12:00:00 PM ET]NVDA$218.69+2.69(+1.25%)NVIDIA and Oracle Expand NVIDIA Vera Rubin to Multi-Gigawatt Scale and Bring NVIDIA Vera CPU to Oracle Cloud Infrastructure[12:00:00 PM ET]

IOVA · NASDAQ

Iovance Biotherapeutics, Inc.

$14.72 +0.96 (+6.98%)

Company overview

Iovance Biotherapeutics, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing cancer immunotherapy products designed to harness the power of a patient's immune system to eradicate cancer cells. It has six ongoing Phase 2 clinical studies, including C-144-01, of its lead product candidate lifileucel for the treatment of metastatic melanoma; C-145-04, of lifileucel for recurrent, metastatic, or persistent cervical cancer; and C-145-03, of its product candidate LN-145 for recurrent and/or metastatic head and neck squamous cell carcinoma. The company has collaborations and licensing agreements with H. Lee Moffitt Cancer Center, M.D. Anderson Cancer Center, Ohio State University, Centre hospitalier de l'Université de Montreal, Cellectis S.A., and Novartis Pharma AG. Iovance Biotherapeutics, Inc. was formerly known as Lion Biotechnologies, Inc.

Sector
Healthcare
Industry
Biotechnology
Exchange
NASDAQ
Market cap
$6.7B
Employees
838
Headquarters
San Carlos, CA
Website
iovance.com
CEO
Frederick G. Vogt
Listed
October 15, 2010
P/E
-16.02
Dividend yield
0.00%

Company financials

Revenue
$286M
Gross profit
$327M
Operating income
-$363M
EBITDA
-$327M
Net income
-$354M
EPS
-$0.92
Total assets
$926M
Total debt
$46.8M
Gross margin
114.51%
Net margin
-123.90%
Earnings yield
-6.24%

Revenue segmentation

By product (FY 2025)
By region (FY 2025)

Showing FY 2025

Price chart

2.796.059.3212.5915.85
IOVA 1D NASDAQ O14.05H14.20L13.36C13.76-0.33 (-2.34%)Vol1.82M

News

15-min delaySigned-out view is delayed 15 minutes. Log in on Pro for the live news desk.

Start 7-day free trial See live plans
Source
Date
Type
Ticker Type Headline Source Published
IOVAIovance Biotherapeutics, Inc. Stock news Best Momentum Stocks to Buy for October 27th Zacks Investment Research
IOVAIovance Biotherapeutics, Inc. Stock news Why Investors Need to Take Advantage of These 2 Medical Stocks Now Zacks Investment Research
IOVAIovance Biotherapeutics, Inc. Press release Iovance Biotherapeutics to Report Third Quarter 2026 Financial Results and Corporate Updates on Thursday, November 5, 2026 GlobeNewswire
IOVAIovance Biotherapeutics, Inc. Press release Immuno-Oncology Emerges as a Major Force in the Global Cancer Treatment Market GlobeNewswire
IOVAIovance Biotherapeutics, Inc. Press release Iovance Announces Data Showing Durable Responses with Lifileucel TIL Cell Therapy in Advanced Soft Tissue Sarcomas at ESMO 2026 GlobeNewswire
IOVAIovance Biotherapeutics, Inc. Press release Iovance Presents New Data at ESMO 2026 Demonstrating Deep, Durable Responses with Lifileucel TIL Cell Therapy Plus Pembrolizumab in Frontline Advanced Melanoma GlobeNewswire
IOVAIovance Biotherapeutics, Inc. Press release Iovance Highlights TIL Cell Therapy Platform Across Solid Tumors at the European Society for Medical Oncology (ESMO) Congress 2026 GlobeNewswire
IOVAIovance Biotherapeutics, Inc. Stock news Undercovered Dozen: Hess Midstream, Iovance Biotherapeutics, Netlist, And More Seeking Alpha
IOVAIovance Biotherapeutics, Inc. Press release Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4) GlobeNewswire
IOVAIovance Biotherapeutics, Inc. Stock news 55,275 Shares of Iovance Biotherapeutics, Inc. $IOVA Purchased by Corient Private Wealth LP Defense World
IOVAIovance Biotherapeutics, Inc. Stock news Iovance: Buy Now Before Many Growth Catalysts Kick In Seeking Alpha
IOVAIovance Biotherapeutics, Inc. Press release Iovance Biotherapeutics Appoints Noah Berkowitz, M.D., Ph.D., as Chief Medical Officer GlobeNewsWire
IOVAIovance Biotherapeutics, Inc. Stock news IOVA Stock Hits 52-Week High on Raised Revenue Outlook for 2026 Zacks Investment Research
IOVAIovance Biotherapeutics, Inc. Stock news Iovance Biotherapeutics (IOVA) Surges 31.5%: Is This an Indication of Further Gains? Zacks Investment Research
IOVAIovance Biotherapeutics, Inc. Stock news Iovance Biotherapeutics' Amtagvi Demand Drives 2026 Revenue Guidance Bump, Stock Soars Benzinga
IOVAIovance Biotherapeutics, Inc. Press release High-Stakes October has these Biotechs Entering Crucial Stretch GlobeNewswire
IOVAIovance Biotherapeutics, Inc. Stock news Major Indexes Slide as Investors Digest Consumer Sentiment Data Schaeffers Research
IOVAIovance Biotherapeutics, Inc. Press release Iovance Biotherapeutics Raises Full Year 2026 Revenue Guidance to $410 to $420 Million GlobeNewsWire
IOVAIovance Biotherapeutics, Inc. Stock news Why Iovance Biotherapeutics Stock Was on Fire Today The Motley Fool
IOVAIovance Biotherapeutics, Inc. Stock news Iovance Maps TIL Therapy Expansion After Record Revenue and Margin Gains MarketBeat
See more
FAQ

Questions about Iovance Biotherapeutics, Inc.

What does Iovance Biotherapeutics, Inc. do?
Iovance Biotherapeutics, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing cancer immunotherapy products designed to harness the power of a patient's immune system to eradicate cancer cells. It has six ongoing Phase 2 clinical studies, including C-144-01, of its lead product candidate lifileucel for the treatment of metastatic melanoma; C-145-04, of lifileucel for recurrent, metastatic, or persistent cervical cancer; and C-145-03, of its product candidate LN-145 for recurrent and/or metastatic head and neck squamous cell carcinoma. The company has collaborations and licensing agreements with H. Lee Moffitt Cancer Center, M.D. Anderson Cancer Center, Ohio State University, Centre hospitalier de l'Université de Montreal, Cellectis S.A., and Novartis Pharma AG. Iovance Biotherapeutics, Inc. was formerly known as Lion Biotechnologies, Inc.
What is IOVA's market cap?
Iovance Biotherapeutics, Inc. (IOVA) is a listed stock with a live quote. The latest market cap on this page is $6.7B.
Where is Iovance Biotherapeutics, Inc. headquartered?
Iovance Biotherapeutics, Inc. is headquartered in San Carlos, CA.
How do I get IOVA news from the API?
Call GET /v1/news?tickers=IOVA. Add type=news, type=press_release, or type=legal to take one feed. Pro keys search the full archive in real time. Free keys are delayed 15 minutes and return the last year. Signed-out visitors and Free accounts see that same year on this page. Pro sees the full archive.
How far back does IOVA news go?
Signed-out visitors and Free accounts see the last year of stock news, press releases, and legal notices for IOVA, 15 minutes behind, and each headline links to the publisher. Pro, including the 7-day trial, sees the full archive as headlines are ingested. A Free API key returns the last year. Pro keys search the full archive.
Is the IOVA price on this page from the API?
The price and daily change update during the US session for every visitor. That quote is context on this page. It is not part of the news API. The chart is one candle per session from the start of 2020. 1W, 1M, and 1Y group those sessions.
Can I use the Pro plan commercially?
No. The Pro plan cannot be used for commercial work. A product you sell, work you do for a client, or redistribution of the feed needs a custom plan and a license. Email [email protected].

Real-time stock news for $15 a month.

Start a 7-day Pro trial. A card is required. REST, WebSocket, and MCP are included, with 1,000 REST requests a day. You won't be charged during the trial. Unless you cancel, the card is billed for Pro when it ends.

Start 7-day free trial Read the docs